CD160-activating NK cell effector functions depend on the phosphatidylinositol 3-kinase recruitment
- PMID: 17307798
- DOI: 10.1093/intimm/dxm005
CD160-activating NK cell effector functions depend on the phosphatidylinositol 3-kinase recruitment
Abstract
CD160 NK cell-activating receptor is a glycosyl-phosphatidylinositol-anchored molecule that, upon specific engagement, triggers both cytotoxicity and a unique cytokine production [IFN-gamma, tumor necrosis factor-alpha (TNF-alpha) and IL-6] through an undefined signaling pathway. In the current study, we have identified several signaling molecules recruited after mAb-specific CD160 engagement in freshly isolated human circulating NK cells. Using confocal microscopy, we found that CD160 engagement induces the recruitment and co-localization of phosphorylated molecules with redistributed, capped CD160 at the cell surface. We then demonstrated that phosphatidylinositol 3-kinase (PI3K) signaling molecule is required for CD160-mediated cytotoxicity and cytokine release. First, we observed by confocal microscopy that engagement of CD160 induces its polarization and co-localization with PI3K. Second, we showed that pharmacological inhibitors of PI3K abrogate both CD160-mediated cytotoxicity and IFN-gamma, TNF-alpha and IL-6 cytokine release. We further found that CD160 engagement induced marked phosphorylation of Akt, as evidenced by western blotting. We identified additional CD160-mediated signaling molecules recruited downstream and upstream of PI3K. Both induction of phosphorylated ERK molecules after CD160-specific engagement and prevention of CD160-induced cytokine release by MEK pharmacological inhibitor indicate that ERK downstream pathway is implicated. Similarly, we identified that Syk molecule upstream of PI3K is involved in the signaling cascade mediated by CD160 engagement. Two different Syk-specific inhibitors blocked CD160-mediated cytokine release, and CD160-specific engagement induced the enhancement of phosphorylated Syk proteins. These data demonstrate that PI3K is a crucial signaling element for both effector functions of the CD160 NK cell-activating receptor.
Similar articles
-
Cutting edge: engagement of CD160 by its HLA-C physiological ligand triggers a unique cytokine profile secretion in the cytotoxic peripheral blood NK cell subset.J Immunol. 2004 Nov 1;173(9):5349-54. doi: 10.4049/jimmunol.173.9.5349. J Immunol. 2004. PMID: 15494480
-
CD160: a unique activating NK cell receptor.Immunol Lett. 2011 Aug 30;138(2):93-6. doi: 10.1016/j.imlet.2011.02.003. Epub 2011 Feb 13. Immunol Lett. 2011. PMID: 21324341 Review.
-
Syk regulation of phosphoinositide 3-kinase-dependent NK cell function.J Immunol. 2002 Apr 1;168(7):3155-64. doi: 10.4049/jimmunol.168.7.3155. J Immunol. 2002. PMID: 11907067
-
UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells.J Immunol. 2002 Jan 15;168(2):671-9. doi: 10.4049/jimmunol.168.2.671. J Immunol. 2002. PMID: 11777960
-
On guard--activating NK cell receptors.Nat Immunol. 2001 Jan;2(1):23-7. doi: 10.1038/83130. Nat Immunol. 2001. PMID: 11135574 Review.
Cited by
-
CD160 activation by herpesvirus entry mediator augments inflammatory cytokine production and cytolytic function by NK cells.J Immunol. 2013 Jul 15;191(2):828-36. doi: 10.4049/jimmunol.1300894. Epub 2013 Jun 12. J Immunol. 2013. PMID: 23761635 Free PMC article.
-
CD160Ig fusion protein targets a novel costimulatory pathway and prolongs allograft survival.PLoS One. 2013 Apr 4;8(4):e60391. doi: 10.1371/journal.pone.0060391. Print 2013. PLoS One. 2013. PMID: 23593209 Free PMC article.
-
CD160 is essential for NK-mediated IFN-γ production.J Exp Med. 2015 Mar 9;212(3):415-29. doi: 10.1084/jem.20131601. Epub 2015 Feb 23. J Exp Med. 2015. PMID: 25711213 Free PMC article.
-
Differential and tumor-specific expression of CD160 in B-cell malignancies.Blood. 2011 Aug 25;118(8):2174-83. doi: 10.1182/blood-2011-02-334326. Epub 2011 Jun 28. Blood. 2011. PMID: 21715317 Free PMC article.
-
Tyrosine kinase inhibition to improve anthracycline-based chemotherapy efficacy in T-cell lymphoma.Br J Cancer. 2019 Oct;121(7):567-577. doi: 10.1038/s41416-019-0557-8. Epub 2019 Sep 2. Br J Cancer. 2019. PMID: 31474759 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
Miscellaneous